“Seattle Genetics had a miraculous birth. No one believed we could convince Bristol Myers Squibb to out-license technology to a couple of former employees. It took a year to complete that deal in 1998, but by 2001 we were publicly traded.

- Dr. Perry Fell, CEO

Seattle Genetics was a biotechnology company established to develop monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. OVP helped the founding team buy out the technology portfolio from a large pharmaceutical firm, then grew the company all the way to a successful IPO.